[Preliminary assessment of ginkgo biloba (Ginkofar) in patients with dementia].
This preliminary open-label study was undertaken to assess the efficacy and tolerability of ginkgo biloba (Ginkofar) (manufactured by Biofarm Poznań) during a 6-month period in Alzheimer type dementia, vascular and mix dementia. Patients were required to have at entry a diagnosis of dementia Alzheimer type or vascular according to ICD-10 criteria. The presence of both types of dementia was classified as mix dementia. 30 patients were included into the study. Overall 27 patients entered treatment and completed a 6 months period. Results of clinical scales (IADL, Clock Test) during period of treatment (baseline, 3 months and 6 months) were stable. MMSE results demonstrated slight benefit. The results show that ginkgo biloba was well tolerated. The patients treated with Ginkofar remaining in the study demonstrate no clinically evident loss of cognitive function.